In Zurich, Singapore, Dubai and a growing list of other cities, a new kind of medical practice is doing brisk business: the longevity clinic. For fees that range from the price of a holiday to the price of a car, clients receive days of testing — blood panels, body composition scans, VO2 max, epigenetic age clocks — and a personalised programme intended not merely to prevent disease but to slow ageing itself.
The premise rests on a genuine scientific development. Researchers can now estimate “biological age” from chemical marks on DNA, and these epigenetic clocks predict mortality and disease risk better than birthdays do. Second-generation clocks, trained on clinical biomarkers rather than just age, respond measurably to interventions in trials: the CALERIE study, in which adults ate slightly less for two years, found a small but real slowing in a clock designed to measure the pace of ageing. That is a long way from the fountain of youth — but it is not nothing, and it has been enough to build an industry on.
What the Clinics Actually Do
Strip away the branding and a good longevity clinic looks like exceptionally thorough preventive medicine: cardiovascular risk mapped in detail, metabolic health optimised, sleep and strength measured and trained, cancer screening brought forward, hormones and deficiencies corrected. Clients are prescribed exercise with the seriousness of a drug, protein targets, and follow-up testing to see whether the numbers move. Much of this is simply the medicine that time-poor health systems fail to deliver — which may explain the sector’s growth better than any breakthrough, as our health coverage has observed.
The frontier offerings are where scrutiny sharpens: off-label metformin and rapamycin for ageing itself (neither is approved for that purpose), NAD boosters, plasma-related therapies and supplement stacks of heroic size. The evidence here ranges from promising-in-mice to absent, and the field’s own researchers are often the sternest critics of clinics selling interventions ahead of the data.
The Measurement Problem
The industry’s deepest problem is its ruler. Epigenetic clocks are statistical tools trained on populations; applying one to an individual involves real noise — the same person’s score can move several “years” between tests taken weeks apart, depending on the clock, the lab and recent illness or stress. Reviews in journals indexed by the Nature group caution that no clock is yet validated as a clinical endpoint: a treatment that moves a clock has not thereby been shown to extend life or health. Clinics that retest clients and celebrate a three-year reversal may be celebrating measurement error.
Regulators are circling accordingly. Advertising claims face new restrictions in several markets, and medical councils have begun reminding doctors that anti-ageing prescribing carries the same evidential duties as any other medicine.
Who Benefits, Honestly
The fairest verdict is asymmetrical. The wealthy clients of longevity clinics will probably live longer — but largely because money buys the unglamorous fundamentals: screening caught early, exercise supervised, sleep protected, risks managed by attentive doctors. The exotic interventions are, for now, expensive lottery tickets laid on top of that solid base. Meanwhile the science the clinics popularise — biological age measurement, geroprotective drug trials like TAME, the metformin study designed to test ageing as a target — is progressing in universities at a more honest pace.
The Bottom Line
Longevity medicine contains a real science, a useful service and a marketing mirage, often under one roof. The clinics are best read as a signal: demand for proactive, measurement-rich healthcare is outrunning what public systems supply. Whether the age-reversing claims mature into medicine will be decided by trials, not testimonials — the same evidence-first standard we applied in our examination of short-video attention research.
